Treatment satisfaction in patients with rrms treated with teriflunomide in routine clinical practice: aubpro study design

Abstract

ObjectivesTeriflunomide is a once-daily immunomodulator approved for the treatment of patients with relapsing-remitting MS (RRMS). Here, we describe the design of AubPRO, a prospective observational study to evaluate treatment satisfaction...